Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America PARP Inhibitor Biomarkers Market, by Product
1.4.2 North America PARP Inhibitor Biomarkers Market, by Application
1.4.3 North America PARP Inhibitor Biomarkers Market, by Services
1.4.4 North America PARP Inhibitor Biomarkers Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. North America PARP Inhibitor Biomarkers Market by Product
4.1 North America Kits Market by Region
4.2 North America Assays Market by Region
Chapter 5. North America PARP Inhibitor Biomarkers Market by Application
5.1 North America Breast Cancer Market by Country
5.2 North America Ovarian Cancer Market by Country
5.3 North America Others Market by Country
Chapter 6. North America PARP Inhibitor Biomarkers Market by Services
6.1 North America BRCA 1 & 2 Testing Market by Country
6.2 North America HRD Testing Market by Country
6.3 North America HRR Testing Market by Country
6.4 North America Others Market by Country
Chapter 7. North America PARP Inhibitor Biomarkers Market by Country
7.1 US PARP Inhibitor Biomarkers Market
7.1.1 US PARP Inhibitor Biomarkers Market by Product
7.1.2 US PARP Inhibitor Biomarkers Market by Application
7.1.3 US PARP Inhibitor Biomarkers Market by Services
7.2 Canada PARP Inhibitor Biomarkers Market
7.2.1 Canada PARP Inhibitor Biomarkers Market by Product
7.2.2 Canada PARP Inhibitor Biomarkers Market by Application
7.2.3 Canada PARP Inhibitor Biomarkers Market by Services
7.3 Mexico PARP Inhibitor Biomarkers Market
7.3.1 Mexico PARP Inhibitor Biomarkers Market by Product
7.3.2 Mexico PARP Inhibitor Biomarkers Market by Application
7.3.3 Mexico PARP Inhibitor Biomarkers Market by Services
7.4 Rest of North America PARP Inhibitor Biomarkers Market
7.4.1 Rest of North America PARP Inhibitor Biomarkers Market by Product
7.4.2 Rest of North America PARP Inhibitor Biomarkers Market by Application
7.4.3 Rest of North America PARP Inhibitor Biomarkers Market by Services
Chapter 8. Company Profiles
8.1 Myriad Genetics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.2 Thermo Fisher Scientific, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 SWOT Analysis
8.3 Illumina, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segment and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Neogenomics, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expenses
8.5 Qiagen N.V.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Agilent Technologies, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 SWOT Analysis
8.7 Merck KGaA
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Bayer AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 AstraZeneca PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. GlaxoSmithKline PLC (GSK)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis
Unique Offerings 